The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MJNA | -80% | -98.51% | -56.87% | -99% |
| S&P | +14.5% | +93.32% | +14.09% | +410% |
Medical Marijuana, Inc. engages in the development, sale, and distribution of hemp oil that contains naturally occurring cannabinoids. It operates through the following divisions: Medical Marijuana Inc, HempMeds and Kannaway. Medical Marijuana Inc operates as the parent company of all divisions. HempMeds distributes hemp oil in the US and internationally. Kannaway is a direct selling division which sells Cannabidiol (CBD) products worldwide. The company was founded in 2003 and is headquartered in San Diego, CA.
The United States' southerly neighbor might legalize adult-use marijuana as early as this week.
An October 2018 Supreme Court ruling is about to make Mexico the third country worldwide to green-light adult-use cannabis.
| Q1 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.79M | -31.6% |
| Gross Profit | $2.17M | -33.3% |
| Gross Margin | 77.89% | -1.9% |
| Market Cap | $1.71M | -82.9% |
| Market Cap / Employee | $0.08M | 0.0% |
| Employees | 22 | 0.0% |
| Net Income | $0.44M | 104.5% |
| EBITDA | $0.27M | 258.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q1 2025 | YOY Change | |
|---|---|---|
| Net Cash | $0.97M | -12.7% |
| Accounts Receivable | $0.31M | -31.2% |
| Inventory | 1.4 | -22.8% |
| Q1 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.94M | -3.1% |
| Short Term Debt | $0.00M | 0.0% |
| Q1 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -0.61% | 4.3% |
| Return On Invested Capital | -41.86% | -18.4% |
| Q1 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $0.06M | -83.1% |
| Operating Free Cash Flow | $0.06M | -83.1% |
| Metric | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.17 | 0.11 | 0.05 | 0.04 | -84.14% |
| Price to Sales | 0.57 | 0.44 | 0.18 | 0.16 | -79.10% |
| Price to Tangible Book Value | -6.28 | -3.32 | -1.16 | -0.87 | -83.79% |
| Price to Free Cash Flow TTM | 2.77 | 3.21 | - | ||
| Enterprise Value to EBITDA | 32.48 | 82.45 | 856.55 | 15.54 | -117.61% |
| Free Cash Flow Yield | 36.1% | 31.1% | - | ||
| Return on Equity | -8.3% | -6.5% | -1.3% | -0.8% | -87.44% |
| Total Debt | $3.02M | $3.10M | $2.85M | $2.94M | -3.08% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
